P2-11-06: PTEN Loss in Asian Triple Negative Breast Cancer Is a Frequent Event Associated with Basal Markers, Tumour Grade and Younger Age of Onset.

BACKGROUND: Triple-negative breast cancer (TNBC) represents a heterogenous disease which differ in characteristic, treatment response and prognosis. We aim to perform in-depth analysis on the clinicopathologic feature and the prognostic value of basal-like and non-basal-like TNBC patients in an Indonesian tertiary hospital.METHODS: We retrospectively included patients diagnosed with TNBC between 2014-2017. Clinical variables were collected from medical record. Expression of epidermal growth factor receptor (EGFR), cytokeratin 5/6 (CK5/6), p53 mutant and androgen receptor (AR) were examined by using immunohistochemistry (IHC).RESULTS: We included 67 subjects, 67.1% were basal-like and the remaining 32.9% were non-basal-like, with mean age of 51 years old, 59.7% subjects had BMI <25 and 40.3% subjects had BMI ≥25; 16.4%, 65.7%, and 17.9% subjects presented with early stage, locally advanced stage, and distant metastasis respectively; T<5 cm was found in 29.9% subjects, while 70.1% subjects had T≥5; 67.2% subjects presented with N-, while 32.8% subjects were N+. The most common histological type was infiltrating ductal (82% of subjects). P53 mutant and AR expressions were positive in 44.8% and 15% subjects, respectively. Basal-like subtype presented with younger age at and had higher expression of AR, while non-basal-like subtype is associated with BMI ≥25 (p<0.05). Basal-like subjects had shorter overall survival (23.9 months (95% CI: 21.9-25.9) vs. 26.1 months (95% CI: 23-29.2).CONCLUSION: Basal-like subtype is associated with worse prognosis, younger age at diagnosis and increased expression of AR, while non-basal-like subtype is associated with higher BMI in Indonesian TNBC.KEYWORDS: TNBC, subtype; basal-like, young age, Indonesia

Download Full-text

Abstract 1339: Role of PTEN loss in basal-like 2 triple negative breast cancer

10.1158/1538-7445.am2017-1339 ◽

2017 ◽

Cited By ~ 1

Author(s):

Ericka L. Smith ◽

Christiana S. Kappler ◽

Stephen P. Ethier

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Pten Loss

Download Full-text

Loss of PTEN Expression Is Associated With IGFBP2 Expression, Younger Age, and Late Stage in Triple-Negative Breast Cancer

American Journal of Clinical Pathology ◽

10.1309/ajcpr11deayptusl ◽

2014 ◽

Vol 141 (3) ◽

pp. 323-333 ◽

Cited By ~ 31

Author(s):

Sarah J. R. Dean ◽

Claire M. Perks ◽

Jeff M. P. Holly ◽

Nirmala Bhoo-Pathy ◽

Lai-Meng Looi ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Late Stage ◽

Triple Negative ◽

Pten Expression ◽

Younger Age

Download Full-text

Should Triple-Negative Breast Cancer (TNBC) Subtype Affect Local-Regional Therapy Decision Making?

American Society of Clinical Oncology Educational Book ◽

10.14694/edbook_am.2014.34.e32 ◽

2014 ◽

pp. e32-e36 ◽

Cited By ~ 7

Author(s):

Meena S. Moran

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Breast Conservation ◽

Definitive Treatment ◽

Partial Breast Irradiation ◽

Breast Irradiation ◽

Regional Management ◽

Younger Age ◽

Tnbc Subtype

The more aggressive biologic characteristics and the current lack of targeted therapy for triple-negative breast cancer (TNBC) make local-regional management decisions challenging for physicians. TNBC is associated with patients of younger age, black race and BRCA1 mutation carriers. Distinctions between BRCA1-associated and sporadic TNBC include increased lifetime risk of ipsilateral and contralateral breast cancer after breast cancer therapy (BCT) for BRCA carriers, which is not shared by sporadic TNBC. However, the presence of a BRCA mutation should not preclude a breast-conservation approach in patients who are otherwise appropriate candidates for BCT. Data suggest that local-regional relapse (LRR) at baseline after BCT appears to be comparable for TNBC and the HER2-positive subgroups, but is about 50% greater than luminal tumors. LRR appears to be similarly increased after mastectomy; thus, TNBC should not be a contra-indication for BCT. Recent hypothesis-generating data suggest less LRR after BCT (where radiation is routinely delivered) than with mastectomy for early-stage TNBC. To date, no specific local-regional guideline recommendations for TNBC exist. Level I outcome data for TNBC using accelerated partial breast irradiation (APBI) and hypofractionated whole-breast irradiation (hWBRT) are lacking. TNBC should be treated with APBI only on clinical trials. Although hWBRT may be considered in TNBC, its association with younger age, advanced disease and use of systemic chemotherapy often precludes its use for this subtype. Until definitive treatment strategies are validated in large datasets and confirmed in randomized trials, TNBC subtype, in and of itself, should not direct local-regional management treatment decisions.

Download Full-text

Research on the Mechanism of Pulsatilla Potentially Useful for the Treatment of Triple Negative Breast Cancer Based on Network Pharmacology

10.21203/rs.3.rs-516623/v1 ◽

2021 ◽

Author(s):

Shilin Li ◽

Yi Fang

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Caspase 3 ◽

Triple Negative ◽

Age Of Onset ◽

Network Pharmacology ◽

Physical And Mental Health ◽

Pulsatilla Chinensis ◽

Potential Methods ◽

Alternative Drugs

Abstract Triple negative breast cancer is a very malignant type of breast cancer. Its age of onset is young and the prognosis is poor, which seriously threatens women's physical and mental health. Pulsatilla Chinensis is a common medicine in traditional Chinese medicine. Application of network pharmacology analysis found that the active ingredients in Pulsatilla can target Caspase-3, NOS3, etc. to exert anti-tumor effects. This discovery will provide new alternative drugs and potential methods for the treatment of triple-negative breast cancer.

Download Full-text